Silybin ACAS# 36804-17-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 36804-17-8 | SDF | Download SDF |
PubChem ID | 31553 | Appearance | Powder |
Formula | C25H22O10 | M.Wt | 482.4 |
Type of Compound | Lignans | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one | ||
SMILES | COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O | ||
Standard InChIKey | SEBFKMXJBCUCAI-HKTJVKLFSA-N | ||
Standard InChI | InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Silybin A Dilution Calculator
Silybin A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.073 mL | 10.3648 mL | 20.7297 mL | 41.4594 mL | 51.8242 mL |
5 mM | 0.4146 mL | 2.073 mL | 4.1459 mL | 8.2919 mL | 10.3648 mL |
10 mM | 0.2073 mL | 1.0365 mL | 2.073 mL | 4.1459 mL | 5.1824 mL |
50 mM | 0.0415 mL | 0.2073 mL | 0.4146 mL | 0.8292 mL | 1.0365 mL |
100 mM | 0.0207 mL | 0.1036 mL | 0.2073 mL | 0.4146 mL | 0.5182 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Malabaricone A
Catalog No.:BCN0842
CAS No.:63335-23-9
- Baishouwubenzophenone
Catalog No.:BCN0841
CAS No.:115834-34-9
- Malabaricone C
Catalog No.:BCN0840
CAS No.:63335-25-1
- Isosecotanapartholide
Catalog No.:BCN0839
CAS No.:102926-01-2
- 8-Epiloganin
Catalog No.:BCN0838
CAS No.:79172-04-6
- Otobaphenol
Catalog No.:BCN0837
CAS No.:10240-16-1
- Rhamnocitrin 3-galactoside
Catalog No.:BCN0836
CAS No.:99878-05-4
- Ganolucidic acid D
Catalog No.:BCN0835
CAS No.:102607-22-7
- 2,6-Dihydroxyacetophenone-4-O-[4',6'-(S)-hexahydroxydiphenoyl]-beta-D-glucose
Catalog No.:BCN0834
CAS No.:1781226-44-5
- Ganoderenic acid K
Catalog No.:BCN0833
CAS No.:942950-94-9
- Gardoside methyl ester
Catalog No.:BCN0832
CAS No.:93930-20-2
- Oxytroflavoside A
Catalog No.:BCN0831
CAS No.:1391144-80-1
- 4-p-Menthan-1,8-diol
Catalog No.:BCN0844
CAS No.:565-48-0
- Neomogroside
Catalog No.:BCN0845
CAS No.:189307-15-1
- Mogroside I-E1
Catalog No.:BCN0846
CAS No.:88901-39-7
- Mogroside I-A1
Catalog No.:BCN0847
CAS No.:88901-46-6
- Mogroside II-B
Catalog No.:BCN0848
CAS No.:942615-25-0
- 11-Oxomogroside I
Catalog No.:BCN0849
CAS No.:918972-06-2
- 11-Deoxymogroside IIIE
Catalog No.:BCN0850
CAS No.:1793003-47-0
- Siraitic acid B
Catalog No.:BCN0851
CAS No.:183374-16-5
- Siraitic acid A
Catalog No.:BCN0852
CAS No.:183374-15-4
- Ciwujianoside A1
Catalog No.:BCN0853
CAS No.:120768-65-2
- Ciwujianoside C3
Catalog No.:BCN0854
CAS No.:114906-74-0
- Notoginsenoside T1
Catalog No.:BCN0855
CAS No.:343962-53-8
Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease.[Pubmed:35705686]
Acta Pharmacol Sin. 2022 Jun 15. pii: 10.1038/s41401-022-00924-4.
Cytochrome P450s are important phase I metabolic enzymes located on endoplasmic reticulum (ER) involved in the metabolism of endogenous and exogenous substances. Our previous study showed that a hepatoprotective agent silybin restored CYP3A expression in mouse nonalcoholic fatty liver disease (NAFLD). In this study we investigated how silybin regulated P450s activity during NAFLD. C57BL/6 mice were fed a high-fat-diet (HFD) for 8 weeks to induce NAFLD, and were administered silybin (50, 100 mg .kg(-1) .d(-1), i.g.) in the last 4 weeks. We showed that HFD intake induced hepatic steatosis and ER stress, leading to significant inhibition on the activity of five primary P450s including CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A in liver microsomes. These changes were dose-dependently reversed by Silybin Administration. The beneficial effects of silybin were also observed in TG-stimulated HepG2 cells in vitro. To clarify the underlying mechanism, we examined the components involved in the P450 catalytic system, membrane phospholipids and ER membrane fluidity, and found that cytochrome b5 (cyt b5) was significantly downregulated during ER stress, and ER membrane fluidity was also reduced evidenced by DPH polarization and lower polyunsaturated phospholipids levels. The increased ratios of NADP(+)/NADPH and PC/PE implied Ca(2+) release and disruption of cellular Ca(2+) homeostasis resulted from mitochondria dysfunction and cytochrome c (cyt c) release. The interaction between cyt c and cyt b5 under ER stress was an important reason for P450s activity inhibition. The effect of silybin throughout the whole course suggested that it regulated P450s activity through its anti-ER stress effect in NAFLD. Our results suggest that ER stress may be crucial for the inhibition of P450s activity in mouse NAFLD and silybin regulates P450s activity by attenuating ER stress.
The Effects of Hydro-Priming and Colonization with Piriformospora indica and Azotobacter chroococcum on Physio-Biochemical Traits, Flavonolignans and Fatty Acids Composition of Milk Thistle (Silybum marianum) under Saline Conditions.[Pubmed:35631705]
Plants (Basel). 2022 May 10;11(10). pii: plants11101281.
Salinity is an important challenge around the world, effecting all physiological and biochemical processes of plants. It seems that seed priming can diminish the negative impacts of salinity. To study the effects of hydro-priming and inoculation with Piriformospora indica (Pi) and Azotobacter chroococcum (Az) on physio-biochemical traits, flavonolignans and fatty acids composition of milk thistle under saline conditions, a greenhouse experiment was carried out. Our results indicated that under salinity, seed priming, especially Pi, improved physio-biochemical properties in milk thistle. Under 120 mM NaCl, inoculation with Pi increased membrane stability index (MSI) and relative water content (RWC) (by 21.86 and 33.43%, respectively). However, peroxidase (POX) (5.57- and 5.68-fold in roots and leaves, respectively), superoxide dismutase (SOD) (4.74- and 4.44-fold in roots and leaves, respectively), catalase (CAT) (6.90- and 8.50-fold in roots and leaves, respectively) and ascorbate peroxidase (APX) (5.61- and 5.68-fold in roots and leaves, respectively) activities increased with increasing salinity. Contrary to salinity, hydro-priming with Az and Pi positively altered all these traits. The highest content of the osmolytes, adenosine triphosphate (ATP) content and rubisco activity were recorded in Pi treatments under 120 mM NaCl. Stearic acid (20.24%), oleic acid (21.06%) and palmitic acid (10.48%) increased, but oil content (3.81%), linolenic and linoleic acid content (22.21 and 15.07%, respectively) decreased under saline conditions. Inoculations of Pi positively altered all these traits. The present study indicated that seed priming with Pi under 120 mM NaCl resulted in maximum silychristin, taxidolin, silydianin, isosilybin, Silybin And silymarin of milk thistle seeds.
Potential antimicrobial, antidiabetic, catalytic, antioxidant and ROS/RNS inhibitory activities of Silybum marianum mediated biosynthesized copper oxide nanoparticles.[Pubmed:35558860]
RSC Adv. 2022 May 11;12(22):14069-14083.
Use of medicinal plants for the biosynthesis of nanoparticles offers several advantages over other synthesis approaches. Plants contain a variety of bioactive compounds that can participate in reduction and capping of nanoparticles. Plant mediated synthesis has the leverage of cost effectiveness, eco-friendly approach and sustained availability. In the current study Silybum marianum, a medicinally valuable plant rich in silymarin content, is used as a reducing and stabilizing agent for the fabrication of nanoparticles. Biosynthesized CuO-NPs were characterized using High Performance Liquid Chromatography (HPLC), Fourier Transform Infrared Spectroscopy (FTIR), X-ray Diffraction (XRD), Scanning Electron Microscopy (SEM), and Dynamic Light Scattering (DLS) techniques. Characterization revealed that CuO-NPs having a crystalline structure showed spherical morphology with an average size of 15 nm. HPLC analysis demonstrated conjugation of various silymarin components, especially the presence of Silybin A (705.06 +/- 1.59 mg g(-1) DW). CuO-NPs exhibited strong bactericidal potency against clinically important pathogenic bacterial strains e.g. Enterobacter aerogenes and Salmonella typhi with an inhibition zone of 18 +/- 1.3 mm and 17 +/- 1.2 mm, respectively. Synthesized nanoparticles indicated a dose dependent cytotoxic effect against fibroblast cells exhibiting a percentage cell viability of 83.60 +/- 1.505% and 55.1 +/- 1.80% at 25 mug mL(-1) and 100 mug mL(-1) concentration, respectively. Moreover, CuO-NPs displayed higher antioxidant potential in terms of (TAC: 96.9 +/- 0.26 mug AAE/mg), (TRP: 68.8 +/- 0.35 mug AAE/mg), (DPPH: 55.5 +/- 0.62%), (ABTS: 332.34 muM) and a significant value for (FRAP: 215.40 muM). Furthermore, enzyme inhibition assays also exhibited excellent enzyme inhibition potential against alpha-amylase (35.5 +/- 1.54%), urease (78.4 +/- 1.26%) and lipase (80.50.91%), respectively. Overall findings indicated that biosynthesized CuO-NPs possess immense in vitro biological and biomedical properties and could be used as a broad-spectrum agent for a wider range of biomedical applications.
Silybin and its congeners: from traditional medicine to molecular effects.[Pubmed:35510639]
Nat Prod Rep. 2022 Jun 22;39(6):1264-1281.
Covering: 2015 up to 2022 (Feb)Silymarin, an extract of milk thistle (Silybum marianum) fruits, has been used in various medicinal applications since ancient times. A major component of silymarin is the flavonolignan Silybin And its relatives isosilybin, silychristin, silydianin, 2,3-dehydrosilybin, and some others. Except for silydianin, they occur in nature as two stereomers. This review focuses on recent developments in chemistry, biosynthesis, modern advanced analytical methods, and transformations of flavonolignans specifically reflecting their chirality. Recently described chemotypes of S. marianum, but also the newest findings regarding the pharmacokinetics, hepatoprotective, antiviral, neuroprotective, and cardioprotective activity, modulation of endocrine functions, modulation of multidrug resistance, and safety of flavonolignans are discussed. A growing number of studies show that the respective diastereomers of flavonolignans have significantly different activities in anisotropic biological systems. Moreover, it is now clear that flavonolignans do not act as antioxidants in vivo, but as specific ligands of biological targets and therefore their chirality is crucial. Many controversies often arise, mainly due to the non-standard composition of this phytopreparation, the use of various undefined mixtures, the misattribution of silymarin vs. silybin, and also the failure to consider the chemistry of the respective components of silymarin.